Adent Capital Corp. (NEX: ANT.H) (“Adent”) and Khiron Life Sciences Corp. (“Khiron”) are pleased to announce that the TSX Venture Exchange (“TSXV”) has conditionally accepted their proposed qualifying transaction (the “Proposed Transaction”), subject to the satisfaction of certain conditions by Adent and Khiron. Upon completion, the Proposed Transaction will result in a reverse takeover of Adent by the shareholders of Khiron.
Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
Khiron is in receipt of all licences required for the cultivation, production, domestic distribution, and international export of both high and low tetrahydrocannabinol and cannabidiol medical cannabis. Khiron is well positioned to continue the expansion of its business plan throughout Latin America.
References is also made to Adent’s press releases dated October 25, 2017, November 7, 2017, December 27, 2017 and January 16, 2018 for additional information relating to Adent, Khiron and the Proposed Transaction.
For additional information on the Proposed Transaction:
Chief Executive Officer
Direct: +1 (416) 459 9979
Chief Financial Officer
Direct: +1 (705) 527 3564
Further information can be accessed via www.khiron.ca
Completion of the Proposed Transaction is subject to a number of conditions including, but not limited to, TSXV acceptance and, if applicable, pursuant to policies of the TSXV, majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed, or at all.
Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Adent should be considered highly speculative.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) has in any way passed upon the merits of the Proposed Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.
This news release contains “forward-looking information” within the meaning of applicable securities laws including statements regarding the terms and conditions of the Proposed Transaction, as well as information relating to Khiron. The information about Khiron contained in the press release has not been independently verified by Adent. Although Adent believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because Adent can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not proceed with the Proposed Transaction; that the ultimate terms of the Proposed Transaction will differ from those that currently are contemplated; and that the Proposed Transaction will not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). The terms and conditions of the Proposed Transaction may change based on Adent’s due diligence and the receipt of tax, corporate and securities law advice for both Adent and Khiron. The statements in this press release are made as of the date of this release. Adent undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Adent, Khiron, their securities, or their respective financial or operating results (as applicable).